Abstract
Staphylococcus aureus (S. aureus) possesses numerous virulence factors, with the increasing prevalence of drug-resistant strains heightening the threat posed by this pathogen. Staphylococcal enterotoxin B (SEB), a highly conserved toxin secreted by S. aureus, is also recognized as a potential bioweapon with super-antigenic activity. SEB represents a promising target in efforts to combat infections caused by S. aureus. We developed mRNA-based vaccine and antibody targeting SEB for both prophylactic and therapeutic purposes in varying S. aureus infection conditions. The mSEB mRNA vaccine (10 μg per mouse) induces more robust and persistent immune responses, including higher antibody titers and specific cellular immune responses, compared to immunization with 30 μg of mSEB protein adjuvanted with aluminum phosphate. Additionally, the anti-SEB mRNA antibody maintains secretion of anti-SEB monoclonal antibody (mAb) with a dosage that is 10 times lower than purified protein administration. The mRNA-based antibody exhibits superior pharmacokinetic profiles compared to its protein counterparts, efficiently neutralizing SEB and clearing S. aureus from circulation. Both the mRNA vaccine and mRNA antibody demonstrate preventive and therapeutic effects by eliciting specific immune responses and generating high-affinity antibodies in mice.
Introduction
Staphylococcus aureus (S. aureus) remains a persistent global health threat, particularly due to the rise of multi-drug resistant strains like MRSA. One of its most dangerous virulence factors is Staphylococcal enterotoxin B (SEB). SEB is a "superantigen"—a toxin that causes the immune system to overreact wildly, triggering a "cytokine storm" that can lead to organ failure and death. Because of its potency, SEB is classified as a potential bioweapon.
Current countermeasures, such as protein-based vaccines or injected monoclonal antibodies, face several hurdles: rapid clearance from the body, dependency on chemical adjuvants, and manufacturing complexity. This research explores an mRNA-based platform to turn the body’s own cells into "bio-factories" for both vaccine antigens and therapeutic antibodies, offering a more potent and efficient alternative.
Methods
The team developed two distinct mRNA-based tools delivered via Lipid Nanoparticles (LNPs):
- The Vaccine (mSEB mRNA): This encodes a mutated version of the SEB toxin (mSEB) that retains its structural shape to train the immune system but loses its toxic superantigen activity.
- The Antibody (anti-SEB mRNA): This encodes the heavy and light chains of a high-affinity human antibody.
To maximize efficacy, the researchers optimized the mRNA architecture. They tested various Untranslated Regions (UTRs) and found that UTRs derived from the Trastuzumab (TS) gene significantly boosted antibody secretion. They also determined that a 2:1 molar ratio of heavy-chain to light-chain mRNA produced the highest antibody yields.
Key Results
Dose Sparing and Enhanced Immune Response
The mRNA platform proved remarkably efficient. The mRNA vaccine (10 μg) induced a more robust immune response than a 30 μg dose of the traditional protein vaccine. Similarly, the mRNA-encoded antibody was effective at a dose 10 times lower than the purified protein version. Beyond antibody production, the mRNA vaccine triggered a strong T-cell response (IFN-γ and IL-4 secretion) and a three-fold increase in the maturation of dendritic cells, which are critical for long-term immune memory.
Superior Pharmacokinetics
Unlike injected protein antibodies that peak immediately and then decline rapidly, mRNA-encoded antibodies are produced endogenously over time. This leads to a higher peak concentration (~45 μg/mL at 24 hours) and a more sustained presence in the bloodstream.
Prophylactic and Therapeutic Efficacy
The platform was tested in several lethal challenge models in mice:
- Prophylaxis: Mice vaccinated with mSEB mRNA showed 100% survival against a lethal SEB toxin challenge. Against a highly virulent S. aureus strain (ST59), the mRNA vaccine provided 60% protection, compared to only 10% in the control group.
- Therapy: Administering the anti-SEB mRNA antibody just one hour after infection significantly reduced the bacterial load in the liver, spleen, and kidneys.
- Cytokine Storm Suppression: The mRNA antibody successfully neutralized SEB in vivo, preventing the massive release of pro-inflammatory cytokines (like TNF-α and IFN-γ) that usually leads to sepsis.
Discussion and Future Directions
This study serves as a powerful proof-of-concept that mRNA technology can be extended beyond viral targets to tackle complex bacterial pathogens and their toxins. While SEB is a major virulence factor, future "universal" vaccines might need to target multiple toxins simultaneously.
Further validation in non-human primates is required to confirm these results, as the human immune response to superantigens can be even more sensitive. Additionally, future research will evaluate the long-term safety and potential for immune exhaustion if mRNA antibodies are expressed for extended periods. Nonetheless, this mRNA-based approach represents a significant advancement in the fight against drug-resistant S. aureus.
Summary updated